Showing results (141-150 of 344) with videos related to
Sort By:
Pageof 35
Ejhaem|May 7, 2025
Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell TherapyYoshiaki Marumo, Masaki Ri, Toru Ebina, et al.Plos One|September 20, 2023
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumorsKaoru Fujikawa, Takuro Saito, Koji Kurose, et al.Japanese Journal of Cancer Research : Gann|June 25, 2002
MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)Masato Ito, Shinsuke Iida, Hiroshi Inagaki, et al.International Journal of Hematology|June 19, 2010
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myelomaShinsuke Iida, Takaaki Chou, Shinichiro Okamoto, et al.Cancer Science|January 17, 2017
Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in JapanKenshi Suzuki, Masaki Ri, Takaaki Chou, et al.Plos One|January 23, 2025
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysisShinsuke Iida, Yusuke Yasutomi, Yevgeniy Samyshkin, et al.Oncology Letters|June 22, 2018
Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myelomaShiori Kinoshita, Masaki Ri, Takashi Kanamori, et al.International Journal of Hematology|October 10, 2020
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVORNaoki Takezako, Hirohiko Shibayama, Hiroshi Handa, et al.Leukemia|May 17, 2019
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)Philippe Moreau, Shaji Kumar, Ralph Boccia, et al.International Journal of Hematology|February 15, 2002
Superior mesenteric venous thrombosis associated with a familial missense mutation (Pro626Leu) in the SHBG-like domain of the protein S moleculeMiyuki Kato, Shinsuke Iida, Mikinori Sato, et al.Pageof 35